Lucis
Paris-based preventive healthcare startup analysing 110+ biomarkers and using clinically reviewed AI to guide personalised prevention.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Daily News – May 26, 2026
Listen to the episodeAbout Lucis
Lucis builds a preventive health platform based on biomarkers, longitudinal data and physician-reviewed AI insights. The new $20M Series A strengthens its European preventive-health positioning, with more than 10,000 users and planned expansion into Spain, Germany and Italy by the end of 2026. The service targets consumers in France, the UK, Ireland and Portugal, competing with platforms such as InsideTracker, Function Health and ZOE in the biomarker and personalised health space. The $20M Series A funds geographic expansion.
The Story
Founded in 2025 by Maxime Berthelot and Baptiste Debever.
How Lucis works
Business Model
Consumer health platform combining testing, app experience and longitudinal monitoring.
Revenue Model
Not verified; likely direct-to-consumer testing and membership model.
Products & Services
Key Products
- Biomarker testing
- AI health companion
- Physician-reviewed insights
Core Use Cases
- Preventive health
- Biomarker monitoring
- Lifestyle guidance
- Follow-up testing
Market & Clients
Key Customers
Consumers in France, UK, Ireland and Portugal.
Geographic Presence
How Lucis competes
Competitors
Competitive Advantages
- Physician-reviewed AI insights
- 110+ biomarkers
- Longitudinal monitoring
- European expansion plan
How Lucis grows
Growth Strategy
Expand into Spain, Germany and Italy by the end of 2026.
Distribution Model
Direct-to-consumer health platform.
Moat (Defensibility)
Longitudinal biomarker dataset and clinical review workflow.
Regulatory Context
Health data, medical oversight and consumer health regulation across European markets.
Key Risks
- Medical regulation
- Clinical trust
- Data privacy
- Consumer retention
Strategic Insights
- Prevention requires integration between biological data, AI and clinical oversight.
- Longitudinal data can become a moat if users retest over time.
- European expansion will require medical credibility and local compliance.
Funding & Investors
Total Funding
Funding Rounds
- 2026 - Series A: $20M
Lead: Singular
Key Investors
Founding Team
Founders
Key Metrics
Lessons from Lucis
- In healthtech, speed and clinical trust must scale together.
- AI is more credible when it explains concrete actions, not just anomalies.
- Retention can come from measurable improvement in personal health data.
Similar Startups
Uncovr
Surgical AI startup analysing procedures to generate operative reports, coding recommendations and usable clinical records.
Read AnalysisNeko Health
Neko Health is a unicorn-scale company with an indicative valuation of $2B. It operates in preventive health by building preventive health scanning and diagnostics clinics.
Read AnalysisRainbow Crops
Belgian agritech, a VIB spin-off, developing an AI-powered platform to accelerate new crop variety development.
Read Analysis